CAS: 627-95-2; 5-Aminopentanoic Acid Hydrochloride

相似化合物

2173111-73-2 660-88-8 123622-48-0

上下游产品

CAS号70320-18-2 5-(Methoxycarbo... | CAS号138286-84-7 Methyl N-(trich... | CAS号5454-83-1 5-溴戊酸甲酯 | CAS号660-88-8 5-氨基戊酸 | CAS号675-20-7 2-氮己环酮 | CAS号23135-50-4 5-(苄氧羰氨基)戊酸 | CAS号63984-02-1 5-氨基戊酸甲酯

哌啶酮置于盐酸,水体系中,化学反应 24.0H,以98%的收率获得产物5-氨基戊酸盐酸盐
参考文献:从2-吡嗪酮,2-羟基嘧啶或2-吡啶酮分别高效制备α-,β-,γ-或δ-氨基酸的两步法
标题:从2-吡嗪酮,2-羟基嘧啶或2-吡啶酮分别高效制备α-,β-,γ-或δ-氨基酸的两步法
摘要:据报道,从2-吡啶酮,2-吡嗪酮或2-羟基嘧啶及其衍生物制备各种α-,β-,γ-和δ-氨基酸的方法是实用,有效的两步程序.该程序适合扩大规模,在大多数情况下,无需色谱纯化产品.这种方法很有用,特别是在合成其他方法无法获得的氨基酸或氘代氨基酸时.
DOI:10.1002/ejoc.201801134

专利信息

专利号:US-9662347-B2
优先权日:2010-05-11
标题 :Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
发明人：LEE BONG HEE; BYUN KYUNG HEE
权利人:LEE BONG HEE; BYUN KYUNG HEE; GACHON UNIV OF INDUSTRY-ACADEMIC COOP FOUND
摘要:The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death. Therefore, the AGE-albumin synthesis inhibitor of the present invention can be valuably used in the diagnosis or treatment of degenerative diseases or autoimmune diseases such as Alzheimer's disease, strokes, Parkinson's disease, amyotrophic lateral sclerosis, rheumatoid arthritis, diabetic retinopathy, AIDS, aging, pulmonary fibrosis, spinal cord injuries, etc.

专利号:US-9371387-B2
优先权日:2011-11-10
标题 :Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient
发明人：LEE BONG HEE; BYUN KYUNG HEE
权利人:UNIV GACHON IND ACAD COOP FOUND
摘要:Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction.

专利号:CA-2840900-A1
优先权日:2011-11-10
标题:Composition for prevention or treatment of ischemic cardiac disease,comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient

专利号:CA-2964760-C
优先权日:2011-11-10
标 题 :Composition for prevention or treatment of ischemic cardiac disease,comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient

专利号:CA-2964760-A1
优先权日:2011-11-10
标 题:Composition for prevention or treatment of ischemic cardiac disease,comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient

专利号:US-2014234343-A1
优先权日:2011-11-10
标题:Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient